SCHEMBL18200715

SCHEMBL18200715

c1ccc(-c2cc(-c3cnc(-c4nc5ccccc5c5c4ccc4ccccc45)cn3)nc(-c3ccccc3)n2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.42
NPC1 O15118 3/20 0.42
RAB9A P51151 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
LMNA P02545 1/20 0.42
RECQL P46063 1/20 0.42
ALDH1A1 P00352 2/20 0.41
HPGD P15428 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
NTSR1 P30989 1/20 0.38
ACHE P22303 1/20 0.38
ATM Q13315 1/20 0.37
PTGES O14684 1/20 0.37
NQO2 P16083 1/20 0.36
ADORA2A P29274 1/20 0.36
ADORA1 P30542 1/20 0.36
MAPK1 P28482 1/20 0.36
TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18201262 0.98 MAPT (0.40) MAPTNPC1RAB9ASMN1; SMN2LMNA
SCHEMBL18201263 0.98 MAPT (0.40) MAPTNPC1RAB9ASMN1; SMN2LMNA
SCHEMBL18201261 0.98 MAPT (0.40) MAPTNPC1RAB9ASMN1; SMN2LMNA
SCHEMBL18200719 0.90 KDM4E (0.41) MAPTNPC1RAB9ASMN1; SMN2LMNA
SCHEMBL18201059 0.89 MAPT (0.41) MAPTNPC1RAB9ASMN1; SMN2LMNA
SCHEMBL18201184 0.89 MAPT (0.44) MAPTNPC1RAB9ASMN1; SMN2LMNA
SCHEMBL18200807 0.88 NPC1 (0.42) MAPTNPC1RAB9ASMN1; SMN2LMNA
SCHEMBL18200545 0.88 MAPT (0.40) MAPTNPC1RAB9ASMN1; SMN2LMNA
SCHEMBL18200700 0.88 DHODH (0.41) MAPTNPC1RAB9ASMN1; SMN2LMNA
SCHEMBL18200692 0.88 DHODH (0.41) MAPTNPC1RAB9ASMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9728731-B2 Heterocyclic compound and organic light emitting device using same HEESUNG MATERIAL LTD. (KR) 2017-08-08 US disclosed
US-9728731-B2 Heterocyclic compound and organic light emitting device using same HEESUNG MATERIAL LTD. (KR) 2017-08-08 US disclosed
US-20160380208-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME HEESUNG MATERIAL LTD. (KR) 2016-12-29 US disclosed
EP-3088392-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME Heesung Material Ltd. (KR) 2016-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160380208-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME NOTUM, DDT, CRY1 MAPT 1937/4885NPC1 3875/4885RAB9A 2864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.